The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "The Corporate Reputation of Pharma 2015 - The Perspective of 139 Patient Groups with an Interest in Diabetes" report to their offering.

This report is based on the findings of a November 2015-January 2016 survey exploring the views of 139 patient groups with an interest in diabetes worldwide. The report provides feedback on the corporate reputation of the pharma industry during 2015, from the perspective of these patient groups, as well as the performance of 21 pharma companies for six key indicators that influence corporate reputation. Results are compared with those of the previous year.

There is growing distrust of pharma in light of several recent and dramatic increases in drug prices in the US. Global US-based patient group specialising in diabetes

Profiles Of the 21 Companies, According To the Neurological Patient Groups Familiar with These Companies, or Have Worked With Them

Each profile contains

Company Background Information

- Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. Increase in revenue over the previous year or decrease in revenue.

- The profiled company's main treatment subject areas (and areas of R&D).

- A mission statement from the profiled company.

How the Company Has Performed At Six Indicators of Corporate Reputation

- The profiled company's performance at the six indicators of corporate reputation in 2015, according to the neurological patient groups familiar with the company.

- The profiled company's performance at the six indicators of corporate reputation, according to the neurological patient groups that have worked with the company.

- How the profiled company performed among neurological patient groups for different countries/regions, compared with the company's global averages for neurological patient groups in 2015.

How the Company Ranks For Corporate Reputation Compared With Other Companies

- The profiled company's rankings among neurological patient groups in 2015 for the six indicators of corporate reputation, compared with 20 other companies.

- The profiled company's rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies.

Companies Mentioned

- AbbVie

- Actavis

- Amgen

- AstraZeneca

- Bayer

- Boehringer Ingelheim

- B-MS

- Eli Lilly

- GSK

- Janssen

- Menarini

- Merck & Co (US)

- Novartis

- Novo Nordisk

- Pfizer

- Roche

- Sandoz

- Sanofi

- Servier

- Takeda

- Teva

For more information about this report visit http://www.researchandmarkets.com/research/wgqxnn/the_corporate

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Corporate Governance, Endocrinology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Corporate Governance, Endocrinology